Inhalation Anesthesia Market 2023 – 2030 By Application, End-use (Hospitals, Ambulatory Surgical Centers), Drug (Sevoflurane, Isoflurane, Desflurane)- Partner & Customer Ecosystem (Product Services, Proposition & Key Features) Competitive Index & Regional Footprints by MarketDigits
Industry : Healthcare | Pages : 187 Pages | Published On : Jul 2023
The valuation of the global inhalation anesthesia market was USD 1.46 billion in 2022, and it is projected to grow at a CAGR of 9.04% from 2023 to 2030. The market expansion can be attributed to the increasing number of surgical procedures and the demand for shorter hospital stays. Inhalation anesthesia offers better patient outcomes compared to the intravenous route. Administering anesthetic agents through the respiratory tract enables controlled and effective sedation, which is both cost-effective and safe. The advantages of the inhalation route over the intravenous route are key drivers of market growth. Inhalation anesthesia is particularly beneficial for patients on ventilation for more than 24 hours, as it facilitates easy monitoring of their health. Thus, the superior patient benefits associated with inhalation anesthesia, compared to the intravenous version, are expected to drive revenue growth during the forecast period.
According to data from the NCBI, approximately 310 million major surgeries are performed worldwide each year, with around 40-50 million occurring in the U.S. and 20 million in Europe. The post-COVID-19 situation has led to an increase in elective surgeries, further fueling the demand for inhalation anesthetics. In 2020, during the COVID-19 pandemic, the Centers for Medicare and Medicaid Services advised hospitals to minimize, postpone, or cancel elective surgeries, resulting in a 48% reduction in surgical procedures in the U.S. Inhaled anesthetics are commonly used to provide general anesthesia. According to data from the National Institutes of Health (NIH), nearly 60,000 individuals undergo surgical procedures under general anesthesia. Life-saving surgeries such as brain surgery, open-heart surgery, or organ transplantation would not be possible without general anesthesia, which drives the demand for inhaled anesthetic drugs.
Inhaled anesthetics contribute to a reduction in patients' overall healthcare expenses. Critically ill patients who have undergone surgery are often admitted to intensive care units (ICUs), which increases healthcare costs due to longer hospital stays. Inhalation anesthesia enables surgeons to adjust the dosage to minimize additional hospitalization, whereas this is not feasible with the intravenous form, thereby reducing patients' overall healthcare expenditure.
Sevoflurane accounted for the largest market share of 62.54% in the inhalation anesthesia industry in 2022. This is due to its potency, rapid action, and faster emergence and recovery compared to other available drugs. However, sevoflurane is more expensive than alternative options. These factors have made sevoflurane the preferred choice for surgeons during surgical procedures for inducing and maintaining anesthesia.
Isoflurane is expected to exhibit the highest growth rate during the forecast period. When considering fresh gas flow rates, sevoflurane and desflurane cost two to three times more than isoflurane. Therefore, isoflurane is the preferred choice of anesthesiologists in developing countries, where cost sensitivity among patients is a significant factor.
In terms of end-use, hospitals dominated the inhalation anesthesia market with a share of 68.54% in 2022. This is attributed to the high number of surgeries performed in hospital settings. Additionally, the presence of anesthesiologists and better patient monitoring services support the dominance of the hospital segment. However, European hospitals are aiming to reduce harmful gas emissions by decreasing the usage of inhalation anesthesia, which may have a negative impact on market growth.
The ambulatory surgical centers segment is projected to grow at the fastest rate during the forecast period. These centers specialize in same-day surgeries, where inhalation anesthetics with fast effects and recovery times are required. As these patients do not require an overnight stay, inhalation anesthesia has a competitive edge in ambulatory surgical center settings.
In terms of applications, the maintenance segment dominated the inhalation anesthesia industry with a share of 84.91% in 2022. Inhaled anesthetics are preferred for maintaining anesthesia as they allow for more precise control and are cost-effective. However, in June 2022, the American Society of Anesthesiologists introduced guidelines to mitigate the impact of greenhouse gases, including a reduction in the use of inhalation anesthesia, which could negatively influence market growth.
Various factors influence the induction of anesthesia, including the therapeutic index of a drug, Minimum Alveolar Concentration (MAC), potency, patient's age, metabolism rate by the kidney/liver, compatibility with other drugs, and blood/gas solubility. Different inhalation general anesthetic agents have distinct mechanisms of action in the central nervous system, depending on their blood and gas solubility and the Minimum Alveolar Concentration (MAC) of the specific drugs.
In 2022, North America emerged as the leading revenue-generating region in the inhalation anesthesia industry, holding a share of 52.37%. This can be attributed to the increased number of surgeries performed in the United States and the successful market presence of key players in the region. Piramal Enterprises Limited, a prominent player in inhalation anesthetics, holds the largest market share for sevoflurane and isoflurane in North America. The substantial presence of registered hospitals in the United States also contributes to the high demand for anesthetic drugs during surgical procedures. Between August 2020 and March 2021, the total number of hospitals in the United States increased by 61%.
The Asia Pacific region is expected to experience the highest growth rate during the forecast period. This growth is driven by the increasing population in the region, resulting in a greater number of surgical procedures being performed. The growing elderly population is also a significant factor contributing to the higher incidence of diseases in the region, thereby increasing the demand for inhaled anesthetic drugs. China, in particular, widely utilizes sevoflurane and desflurane for day surgeries due to their advantages, such as rapid response and faster recovery. However, European regions are focusing on reducing the usage of inhalation anesthetics. For example, in March 2023, Scotland announced a ban on the use of inhaled anesthetic desflurane due to its adverse environmental impact. This initiative is expected to reduce harmful emissions by 40 kilotons.
Key Companies & Market Share Insight
To secure their market shares, the major players in the industry are implementing various strategic initiatives such as mergers and acquisitions, technological collaborations, partnerships, and innovative product developments and launches. Leading companies like Baxter, Abbvie, Halocarbon Life Sciences, Sandoz, and Piramal hold significant market shares. For instance, in January 2019, Sandoz International GmbH introduced Desflurane liquid as an inhalation agent for the induction and maintenance of anesthesia in adults and pediatric patients undergoing inpatient and outpatient surgeries in the United States. This product launch marked the first generic version of Suprane available in the U.S. market.
Some of the key players in the global inhalation anesthesia market include:
• Halocarbon Products Corporation
• AbbVie Inc.
• Lunan Pharmaceutical Group
• Piramal Enterprises Ltd.
• Sandoz International GmbH
• Fresenius Kabi AG
Global Inhalation Anesthesia Market Report Segmentation
This report presents a revenue growth forecast and analyzes the latest trends in each of the sub-segments from 2018 to 2030. The global inhalation anesthesia market report, prepared by Grand View Research, is segmented based on drug, application, end-use, and region for the purpose of this analysis.
Drug Outlook (Revenue, USD Million, 2018 - 2030)
Application Outlook (Revenue, USD Million, 2018 - 2030)
End-Use Outlook (Revenue, USD Million, 2018 - 2030)
• Ambulatory Surgical Centers
Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
• Asia Pacific
o South Korea
• Latin America
• Middle East & Africa
o South Africa
o Saudi Arabia
Table and Figures
At MarketDigits, we take immense pride in our 360° Research Methodology, which serves as the cornerstone of our research process. It represents a rigorous and comprehensive approach that goes beyond traditional methods to provide a holistic understanding of industry dynamics.
This methodology is built upon the integration of all seven research methodologies developed by MarketDigits, a renowned global research and consulting firm. By leveraging the collective strength of these methodologies, we are able to deliver a 360° view of the challenges, trends, and issues impacting your industry.
The first step of our 360° Research Methodology™ involves conducting extensive primary research, which involves gathering first-hand information through interviews, surveys, and interactions with industry experts, key stakeholders, and market participants. This approach enables us to gather valuable insights and perspectives directly from the source.
Secondary research is another crucial component of our methodology. It involves a deep dive into various data sources, including industry reports, market databases, scholarly articles, and regulatory documents. This helps us gather a wide range of information, validate findings, and provide a comprehensive understanding of the industry landscape.
Furthermore, our methodology incorporates technology-based research techniques, such as data mining, text analytics, and predictive modelling, to uncover hidden patterns, correlations, and trends within the data. This data-driven approach enhances the accuracy and reliability of our analysis, enabling us to make informed and actionable recommendations.
In addition, our analysts bring their industry expertise and domain knowledge to bear on the research process. Their deep understanding of market dynamics, emerging trends, and future prospects allows for insightful interpretation of the data and identification of strategic opportunities.
To ensure the highest level of quality and reliability, our research process undergoes rigorous validation and verification. This includes cross-referencing and triangulation of data from multiple sources, as well as peer reviews and expert consultations.
The result of our 360° Research Methodology is a comprehensive and robust research report that empowers you to make well-informed business decisions. It provides a panoramic view of the industry landscape, helping you navigate challenges, seize opportunities, and stay ahead of the competition.
In summary, our 360° Research Methodology is designed to provide you with a deep understanding of your industry by integrating various research techniques, industry expertise, and data-driven analysis. It ensures that every business decision you make is based on a well-triangulated and comprehensive research experience.
- Tailored advice to Drive your Performance
- Product Planning Strategy
- New Product Stratergy
- Expanded Research Scope
- Comprehensive Research
- Strategic Consulting
- Provocative and pragmatic
- Accelerate Revenue & Growth
- Evaluate the competitive landscape
- Optimize your partner network
- Analyzing industries
- Mapping trends
- Strategizing growth
- Implementing plans
Covered Key Topics
Market Growth Drivers
Leading Market Players
Company Market Share
Market Size and Growth Rate
Market Trend and Technological